Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia

Código QR

Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia

Srihari Gopal1, Joris Berwaerts1, Isaac Nuamah1, Kasem Akhras2, Danielle Coppola1, Ella Daly1, David Hough1, Joseph Palumbo11Johnson &amp; Johnson Pharmaceutical Research &amp; Development, LLC, Raritan, NJ, USA; 2Johnson &amp; Johnson Pharmaceutical Services, LLC, Raritan, N...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Srihari Gopal, Joris Berwaerts, Isaac Nuamah, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2011
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/45d7582590bb4d0e9e153426d5bfd21f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Assessing effectiveness of aripiprazole lauroxil vs placebo for the treatment of schizophrenia using number needed to treat and number needed to harm
por: Citrome L, et al.
Publicado: (2019)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
por: Mathews M, et al.
Publicado: (2019)

Caregiver burden in schizophrenia following paliperidone palmitate long acting injectables treatment: pooled analysis of two double-blind randomized phase three studies
por: Srihari Gopal, et al.
Publicado: (2017)

Expansion of guidance for the day 8 initiation dose of paliperidone palmitate to avoid a missed dose
por: Samtani MN, et al.
Publicado: (2013)

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
por: Mathews M, et al.
Publicado: (2018)

Efficacy and safety of paliperidone palmitate 3-month versus 1-month formulation in patients with schizophrenia: comparison between European and non-European population
por: Savitz AJ, et al.
Publicado: (2019)

Defining “Adequately Treated”: A Post Hoc Analysis Examining Characteristics of Patients with Schizophrenia Successfully Transitioned from Once-Monthly Paliperidone Palmitate to Once-Every-3-Months Paliperidone Palmitate
por: O'Donnell A, et al.
Publicado: (2021)

Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia
por: Zhang F, et al.
Publicado: (2015)

Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
por: Takada R, et al.
Publicado: (2018)

Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
por: Nash AI, et al.
Publicado: (2019)

Role of paliperidone palmitate 3-monthly in the management of schizophrenia: insights from clinical practice
por: Lopez A, et al.
Publicado: (2019)

The twenty-ninth day: Accommodating human needs and numbers to the earth's resources
por: Brown, Lester Russell, 1934-
Publicado: (1978)

Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability
por: Gattaz WF, et al.
Publicado: (2020)

Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia
por: Sliwa JK, et al.
Publicado: (2012)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
por: Emsley R, et al.
Publicado: (2018)

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
por: Savitz AJ, et al.
Publicado: (2017)

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia
por: Lambert M, et al.
Publicado: (2020)

Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate Among Veterans with Schizophrenia
por: El Khoury AC, et al.
Publicado: (2021)

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
por: Such P, et al.
Publicado: (2021)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
por: Si T, et al.
Publicado: (2019)

Availability and use of number needed to treat (NNT) based decision aids for pharmaceutical interventions
por: Cassandra Nguyen, et al.
Publicado: (2021)

Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia
por: Takahashi N, et al.
Publicado: (2013)

Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
por: Gopal S, et al.
Publicado: (2020)

Direct squencing from the minimal number of DNA molecules needed to fill a 454 picotiterplate.
por: Mária Džunková, et al.
Publicado: (2014)

Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting
por: Di Lorenzo R, et al.
Publicado: (2019)

Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics
por: Alphs L, et al.
Publicado: (2013)

Do No Harm: The Urgent Need to Reform Short-Term Global Health Experiences
por: Keith Martin
Publicado: (2019)

The cost reduction in hospitalization associated with paliperidone palmitate in the People’s Republic of China, Korea, and Malaysia
por: Chiou CF, et al.
Publicado: (2015)

CT Examinations for COVID-19: A Systematic Review of Protocols, Radiation Dose, and Numbers Needed to Diagnose and Predict
por: Jong Hyuk Lee, et al.
Publicado: (2021)

Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study
por: Si TM, et al.
Publicado: (2015)

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
por: Emsley R, et al.
Publicado: (2017)

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
por: Li HF, et al.
Publicado: (2015)

Factors related to improvement of symptoms, function, and caregiver burden in Chinese patients with schizophrenia after switching to paliperidone palmitate once-monthly from oral antipsychotics
por: Li N, et al.
Publicado: (2018)

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
por: Zhao JP, et al.
Publicado: (2017)

Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies
por: Gopal S, et al.
Publicado: (2013)

The need for structural and community interventions to support HIV care and harm reduction for people who inject drugs in Kenya
por: A. Guise, et al.
Publicado: (2015)

Intoxicación por Haloperidol (Haldol)
por: Filippa,Rolando, et al.
Publicado: (1976)

Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL study
por: Li H, et al.
Publicado: (2018)

Number of daily measurements needed to estimate habitual step count levels using wrist-worn trackers and smartphones in 212,048 adults
por: Jiali Yao, et al.
Publicado: (2021)

Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
por: Zhang H, et al.
Publicado: (2016)